Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

VitaNova Life Sciences (YJGJ) Gains from Investment Securities (2022 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Gains from Investment Securities for 4 consecutive years, with $94031.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 859.79% year-over-year to $94031.0, compared with a TTM value of $84234.0 through Oct 2025, up 759.79%, and an annual FY2023 reading of $3880.0, changed N/A over the prior year.
  • Gains from Investment Securities was $94031.0 for Q4 2025 at VitaNova Life Sciences, up from -$9797.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $94031.0 in Q4 2025 and bottomed at -$9797.0 in Q1 2025.
  • Average Gains from Investment Securities over 4 years is $16318.5, with a median of $3880.0 recorded in 2022.
  • Peak annual rise in Gains from Investment Securities hit 859.79% in 2025, while the deepest fall reached 859.79% in 2025.
  • Year by year, Gains from Investment Securities stood at -$3880.0 in 2022, then skyrocketed by 200.0% to $3880.0 in 2023, then surged by 152.5% to $9797.0 in 2024, then skyrocketed by 859.79% to $94031.0 in 2025.
  • Business Quant data shows Gains from Investment Securities for YJGJ at $94031.0 in Q4 2025, -$9797.0 in Q1 2025, and $9797.0 in Q4 2024.